News and Announcements
YPB Issues Earnings Guidance for 2017; Pre-Tax Profit of 5m for 2017, Substantial Revenue Pipeline Established
- Published May 19, 2016 4:44PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19th May 2016, ASX Announcement
- Substantial revenue pipeline established
- Profit and cashflow breakeven by end of Q1 2017
- Pre-tax profit of 5m for 2017
YPB Group is pleased to provide earnings guidance for the Company’s financial year commencing 1 January 2017.
Progress made since the early 2016 launch of YPB’s end-to-end solution suite has provided the Board with sufficient information to reasonably judge earnings prospects. Significant revenue growth is anticipated in 2016 and 2017, which together with diligent cost management is expected to result in breakeven being reached by the end of Q1 2017 and pre-tax profit of $5m being realised for 2017.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
